Nexthink is a global leader in digital experience management.
The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.
HouseTrip SA operates a prominent holiday rental booking website that connects property owners with guests seeking accommodations. Founded in 2009, the platform features over 300,000 listings in thousands of destinations worldwide, including apartments, villas, and cottages. HouseTrip enables homeowners to advertise their properties and guests to book them securely online, facilitating a seamless rental experience. The company is headquartered in Lausanne, Switzerland, with additional offices in London, United Kingdom, and Lisbon, Portugal. Since its launch in January 2010, HouseTrip has facilitated over 6 million nights booked, establishing itself as one of Europe's largest holiday rental websites. In 2016, HouseTrip became a subsidiary of TripAdvisor Inc.
Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.
HouseTrip SA operates a prominent holiday rental booking website that connects property owners with guests seeking accommodations. Founded in 2009, the platform features over 300,000 listings in thousands of destinations worldwide, including apartments, villas, and cottages. HouseTrip enables homeowners to advertise their properties and guests to book them securely online, facilitating a seamless rental experience. The company is headquartered in Lausanne, Switzerland, with additional offices in London, United Kingdom, and Lisbon, Portugal. Since its launch in January 2010, HouseTrip has facilitated over 6 million nights booked, establishing itself as one of Europe's largest holiday rental websites. In 2016, HouseTrip became a subsidiary of TripAdvisor Inc.
HouseTrip SA operates a prominent holiday rental booking website that connects property owners with guests seeking accommodations. Founded in 2009, the platform features over 300,000 listings in thousands of destinations worldwide, including apartments, villas, and cottages. HouseTrip enables homeowners to advertise their properties and guests to book them securely online, facilitating a seamless rental experience. The company is headquartered in Lausanne, Switzerland, with additional offices in London, United Kingdom, and Lisbon, Portugal. Since its launch in January 2010, HouseTrip has facilitated over 6 million nights booked, establishing itself as one of Europe's largest holiday rental websites. In 2016, HouseTrip became a subsidiary of TripAdvisor Inc.
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
be2 S.à.r.l. is an online matchmaking service founded in 2004, initially launching its platform in Germany. It specializes in connecting individuals seeking long-term relationships, utilizing a scientific personality test to match users effectively. With a focus on international expansion, be2 operates in 37 countries across six continents, making it one of the largest and fastest-growing online matchmaking services in Europe. The company is headquartered in Luxembourg and also maintains an office in Zurich, employing a diverse team of 170 professionals from 43 nationalities. The management team brings extensive experience from various sectors of the online industry and has a proven track record in scaling startups into profitable enterprises.
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
BeamExpress, a spin-off from BeamExpress Inc, is a privately held company working in cooperation with EPFL (The Swiss Federal Institute of Technology) to develop long wavelength VCSELs (Vertical Cavity Surface Emitting Laser) for high-speed optical communications as well as gas spectrometry. BeamExpress is using a unique proprietary fabrication technique – the localized wafer fusion process - developed by the members of the founding team, which provides high performance 1310nm devices up to 10Gb/s but also VCSELs laser sources with high precision wavelengths ranging from 1200nm up to 2000nm for CWDM application and for the gas sensing industry. BeamExpress is a fabless company, outsourcing its production to leading European partners.
SpinX develops and commercializes a programmable lab-on-a-chip platform for applications that ranges from drug discovery to consumer diagnostics. Its products include SpinX Lab, a system to transition from low volume microplate assays to an automated bench-top technology for assays in nanoliter volumes; and workflow, an assay preparation for a panel of enzymatic assays. Bart Van de Vyver and Piero Zucchelli founded SpinX in 2003. It has its headquarters in Geneva in Switzerland.
Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.
BeamExpress, a spin-off from BeamExpress Inc, is a privately held company working in cooperation with EPFL (The Swiss Federal Institute of Technology) to develop long wavelength VCSELs (Vertical Cavity Surface Emitting Laser) for high-speed optical communications as well as gas spectrometry. BeamExpress is using a unique proprietary fabrication technique – the localized wafer fusion process - developed by the members of the founding team, which provides high performance 1310nm devices up to 10Gb/s but also VCSELs laser sources with high precision wavelengths ranging from 1200nm up to 2000nm for CWDM application and for the gas sensing industry. BeamExpress is a fabless company, outsourcing its production to leading European partners.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.
Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.
Kimotion provides front-to-back analog design software, including modeling, sizing and layout tools, addressing high-complexity analog functional blocks. Our software helps circuit designers quickly size and layout complex designs containing thousands of transistors, without compromising design performance. Kimotion is a technology spin-off of the Katholieke Universiteit Leuven, with venture capital funding from Index Ventures and Innovacom. The company has offices near Geneva, Switzerland and Leuven, Belgium.
BeamExpress, a spin-off from BeamExpress Inc, is a privately held company working in cooperation with EPFL (The Swiss Federal Institute of Technology) to develop long wavelength VCSELs (Vertical Cavity Surface Emitting Laser) for high-speed optical communications as well as gas spectrometry. BeamExpress is using a unique proprietary fabrication technique – the localized wafer fusion process - developed by the members of the founding team, which provides high performance 1310nm devices up to 10Gb/s but also VCSELs laser sources with high precision wavelengths ranging from 1200nm up to 2000nm for CWDM application and for the gas sensing industry. BeamExpress is a fabless company, outsourcing its production to leading European partners.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.
BeamExpress, a spin-off from BeamExpress Inc, is a privately held company working in cooperation with EPFL (The Swiss Federal Institute of Technology) to develop long wavelength VCSELs (Vertical Cavity Surface Emitting Laser) for high-speed optical communications as well as gas spectrometry. BeamExpress is using a unique proprietary fabrication technique – the localized wafer fusion process - developed by the members of the founding team, which provides high performance 1310nm devices up to 10Gb/s but also VCSELs laser sources with high precision wavelengths ranging from 1200nm up to 2000nm for CWDM application and for the gas sensing industry. BeamExpress is a fabless company, outsourcing its production to leading European partners.